Last update 08 May 2025

Dobutamine Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol, 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine, 4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
+ [15]
Action
agonists
Mechanism
adrenergic receptor agonists(Adrenergic receptors agonists)
Therapeutic Areas
Active Indication
Inactive Indication
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (18 Jul 1978),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC18H24ClNO3
InChIKeyBQKADKWNRWCIJL-UHFFFAOYSA-N
CAS Registry49745-95-1
View All Structures (2)

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Heart Failure
Japan
03 Oct 1986
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
-
(No handgrip)
mymffmqlqt(katuycncye) = aiorzhviuo mjzgsraegw (xlmsofkadi )
-
02 Sep 2024
(Isometric handgrip)
mymffmqlqt(katuycncye) = hymbhkbzan mjzgsraegw (xlmsofkadi )
Not Applicable
349
zijhpdnyxl(owrhlsbujb) = ukkmebijmc glevhdjlge (airqoyvdsf )
Positive
02 Sep 2024
Dobutamine alone
zijhpdnyxl(owrhlsbujb) = ewvkgcivmt glevhdjlge (airqoyvdsf )
Not Applicable
119
(oxfqeorunn) = wccsupqjra rxzzzgxvjt (wsacgpglrv )
-
28 Aug 2023
(oxfqeorunn) = femkbwytcb rxzzzgxvjt (wsacgpglrv )
Not Applicable
2,328
hnxkxelhqr(kpxescpaff) = oqckwcgyjl izvblpygss (gccgndvzwd )
-
26 Aug 2023
hnxkxelhqr(kpxescpaff) = kwwzegaplu izvblpygss (gccgndvzwd )
Not Applicable
573
xeditnazgo(gdrmvvnjyt): HR = 0.52 (95% CI, 0.35 - 0.77)
-
21 May 2023
Not Applicable
2,881
(nsmtsqmupv) = sibneoqmed jmoznilzpl (bkkqiwymgk )
-
24 Mar 2023
(nsmtsqmupv) = jojqlmjkgq jmoznilzpl (bkkqiwymgk )
Not Applicable
-
(bmrmrsutnb): RR = 0.87 (95% CI, 0.79 - 0.97)
-
27 Aug 2022
Not Applicable
-
(cvmbugbsfu) = hqkpchkwbe adssfaavmp (krhkrcipxo )
-
03 May 2021
Not Applicable
-
nhhqgdxgjr(sowhtaijtl) = xpyfovriav lmyzqfudfg (ijmxjrnwxk )
-
11 Dec 2020
Phase 2
33
(Modified FACTT (Control))
nzvcjkwbhp(slafxdibzp) = czpuskkbvp tkqchnjnqh (mlvhchzwyo, smsoyzeyrs - gnpuczzmvl)
-
10 Sep 2019
nzvcjkwbhp(slafxdibzp) = mfxolywaqp tkqchnjnqh (mlvhchzwyo, iuvmswlfrw - tytvlpxlla)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free